Is American Vanguard Corporation (AVD) a Buy, Sell, or Hold?
American Vanguard Corporation
NYSE:AVD
$2.64 USD
-$0.02 (-0.75%)
- Volume
- 81.77K
- Average Volume
- 360.45K
- Market Capitalization
- $75.52M
- P/E Ratio
- -1.68
- Dividend Yield
- 0.00%
- Price Target
- $17.00
- Year High
- $5.92
- Year Low
- $2.05
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.32
| Source | Headline |
|---|---|
|
American Vanguard Corporation (AVD) Announces Executive Appointment of Hermann Castro as Senior Vice President, Marketing and Business Development at AMVAC
NEWPORT BEACH, CA / ACCESS Newswire / July 1, 2026 / American Vanguard Corporation (NYSE:AVD) today announced that Hermann Castro has joined its executive team as Senior Vice President, Marketing and Business Development. Mr. Castro brings more than 25 years of global leadership experience across the agricultural value chain, including crop protection, seed and traits, production agriculture, and fresh produce systems. accessnewswire.com - 2026-07-01 16:05:00 |
|
American Vanguard Announces Voting Results Of 2026 Annual Meeting Of Stockholders
NEWPORT BEACH, CA / ACCESS Newswire / June 8, 2026 / American Vanguard Corporation (NYSE:AVD) announced the voting results from its Annual Meeting of Stockholders held on June 3, 2026. As to the first of four initiatives, the seven director nominees named in the proxy received more votes "for" than "against"; those persons are: Marisol Angelini, Mark Bassett, Patrick Gottschalk, Douglas Kaye, Steven Macicek, Rubin McDougal and Keith Rosenbloom. accessnewswire.com - 2026-06-08 09:55:00 |
|
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #HodgkinLymphoma--BMS Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma. businesswire.com - 2026-06-01 06:55:00 |
|
American Vanguard Corporation (AVD) Q1 2026 Earnings Call Transcript
American Vanguard Corporation (AVD) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-06 22:51:15 |
|
American Vanguard Reports First Quarter 2026 Results
First Quarter Revenue Growth of 7% to $124 million Gross Margin Expansion of 500 bps Reaffirm Full-Year Outlook; Adjusted EBITDA $44 million to $48 million on Sales of $530 million to $550 million NEWPORT BEACH, CA / ACCESS Newswire / May 6, 2026 / American Vanguard Corporation, a diversified specialty and agricultural products company that develops, manufactures, and markets solutions for crop protection and nutrition, turf and ornamental management and commercial pest control, today reported financial results for the first quarter ended March 31, 2026. Financial and Operational Highlights First Quarter 2026 - versus First Quarter 2025: Net sales of $124 million vs. accessnewswire.com - 2026-05-06 16:05:00 |
|
American Vanguard Announces Date of First Quarter 2026 Earnings Release and Webcast Conference Call
NEWPORT BEACH, CA / ACCESS Newswire / May 4, 2026 / American Vanguard Corporation announced today that it will report financial results for the quarter ended March 31, 2026, on Wednesday, May 6, 2026, after the market closes. In addition, the company will conduct an earnings conference call on that day at 4:30 pm ET/ 1:30 pm PT. CEO Dak Kaye and CFO David Johnson will host the event. accessnewswire.com - 2026-05-04 09:10:00 |
